<DOC>
	<DOCNO>NCT00022191</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy regimen effective urinary tract cancer . PURPOSE : Randomized phase III trial compare effectiveness cisplatin plus gemcitabine without paclitaxel treat patient stage IV urinary tract cancer .</brief_summary>
	<brief_title>Cisplatin Plus Gemcitabine With Without Paclitaxel Treating Patients With Stage IV Urinary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare duration survival patient stage IV transitional cell carcinoma urothelium treat cisplatin gemcitabine without paclitaxel . - Compare duration progression-free survival , response rate , duration response patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center , WHO performance status ( 0 vs 1 ) , presence metastatic disease ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 cisplatin IV 1 hour day 1 2 . Treatment repeat every 28 day maximum 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive paclitaxel IV 1 hour day 1 8 follow cisplatin IV 1 hour day 1 gemcitabine IV 30 minute day 1 8 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month least 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 610 patient ( 305 per treatment arm ) accrue study within 3.04 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV transitional cell carcinoma urothelium ( pure mix ) include bladder , urethra , ureter , renal pelvis T4b , N OR T , N23 OR M1 Ineligible surgery radiotherapy curative intent Measurable evaluable disease No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.25 time normal AST ALT less 2.5 time normal Renal : Glomerular filtration rate least 60 mL/min Calcium normal clinically insignificant Cardiovascular : No clinically significant cardiac arrhythmia No congestive heart failure No complete bundle branch block No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No psychological , familial , sociological , geographical condition would preclude study compliance No grade 3 4 infection without neutropenia No serious concurrent systemic disorder would preclude study therapy No mental disorder would preclude study compliance No grade II great neuropathy No prior concurrent malignancy except appropriately treat carcinoma situ cervix , basal cell carcinoma skin , incidental prostate cancer ( T1 , Gleason score great 6 , PSA le 0.5 ng/mL ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior investigational biologic agent ( e.g. , antiangiogenic product , signal transduction pathway inhibitor , immunomodulators , monoclonal antibody therapy ) At least 4 week since prior immunotherapy Chemotherapy : No prior systemic chemotherapy At least 4 week since prior local intravesical chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No 1 prior course radiotherapy At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Prior urological procedure relieve urinary tract obstruction improve renal function allow ( e.g. , ureteral stent percutaneous nephrostomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>